We have previously described a model of acute lung injury in the mouse in which intravenous administration of lipopolysaccharide (LPS) results in a marked sequestration of neutrophils in the pulmonary microvasculature, although this by itself was not sufficient to induce injury. If the sequestered neutrophils were exposed to zymosan, then a striking increase in pulmonary vascular permeability to albumin was found, suggesting that sequestered neutrophils may produce one or more mediators capable of acting directly on the capillary endothelium. Because activated neutrophils are known to release platelet-activating factor (PAF), we hypothesized that PAF produced locally within the pulmonary capillaries may be the mediator involved. Treatment of mice with the PAF antagonist UK-74,505 prior to administration of zymosan alone or combined LPS and zymosan resulted in a substantial attenuation of lung injury, as measured by the accumulation of extravascular 125 I-labeled human serum albumin. UK-74,505 had no effect on neutrophil sequestration as measured by myeloperoxidase activity in whole lung tissue and as assessed by light microscopy. Administration of UK-74,505 after LPS, but before zymosan, was also effective at inhibiting lung injury but again, neutrophil sequestration was unaffected. In contrast, UK-74,505 had no effect on cobra venom factor-induced lung injury and neutrophil sequestration. These data suggest that PAF production is involved in the increases in pulmonary vascular permeability, but not in the sequestration of neutrophils, induced by zymosan alone or by combined LPS and zymosan treatment. Early treatment with PAF antagonists may be beneficial in preventing the development of acute lung injury in humans. Miotla, J. M., P. K. Jeffery, and P. G. Hellewell. 1998. Platelet-activating factor plays a pivotal role in the induction of experimental lung injury. Am. J. Respir. Cell Mol. Biol. 18:197-204.
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Acute lung injury, such as that associated with the adult respiratory distress syndrome (ARDS), is characterized by a sequestration of neutrophils in the pulmonary microcirculation and an increase in microvascular permeability (1, 2) as well as severe alveolar edema formation. Mortality is often the result of impaired gaseous exchange, hyaline membrane formation, and subsequent alveolar fibrosis. Effective therapeutic intervention remains limited, as the manifestation and diagnosis of lung injury may be many hours after the initiation of pathologic events. The causes connected with the development of ARDS can be a consequence of direct pulmonary insult or other nonpulmonary conditions. Around 50% of ARDS cases are due to sepsis and in these patients, platelet-activating factor (PAF) has been detected at elevated levels in the blood (3, 4) .
Experimental lung injury in animals can be induced by administration of endotoxin or lipopolysaccharide (LPS), whereby the classic symptoms of lung injury, i.e., pulmonary leukostasis (5) and increased pulmonary vascular permeability (6) (7) (8) (9) , are manifested. Increases in PAF-like activity in plasma are also demonstrated in animals treated with endotoxin (10) (11) (12) . In these experimental models, PAF receptor antagonists inhibit several features of endotoxininduced lung injury, including increased pulmonary vascular permeability and pulmonary edema formation (10) . However, increased PAF levels are also detected in the bronchoalveolar lavage fluid of trauma patients and nonseptic patients with ARDS (4, 13) and have therefore been implicated as an effector of the associated pathologic changes. Intravenous injection of PAF results in leukopenia with sequestration of neutrophils in the pulmonary vasculature (14) , increases in pulmonary vascular permeability (15, 16) , and the formation of pulmonary edema (17) .
Despite the data obtained in experimental studies, there is limited clinical experience with PAF antagonists in conditions associated with lung injury such as ARDS, par-ticularly that which is not associated with sepsis. In one phase II study, treatment with the PAF antagonist Lexipafant reduced pulmonary dysfunction in acute pancreatitis (18) . In another multicenter phase III trial, repeated dosing with the PAF antagonist BN 52021 over several days resulted in a significant reduction in the mortality of patients with severe gram-negative sepsis (19) , suggesting that protracted blockade of PAF receptors during the inflammatory cascade may be effective in a subgroup of septic patients; however, lung dysfunction was not measured in this study.
We have previously described a model of acute lung injury in the mouse, wherein intravenous administration of LPS results in a marked sequestration of neutrophils in the pulmonary microvasculature, although this by itself was not sufficient to induce injury, as assessed by the extravascular accumulation of radiolabeled albumin (20) . However, if the sequestered neutrophils were exposed to zymosan, a particulate stimulus, then a striking increase in pulmonary vascular permeability to albumin was found. Zymosan itself, like cobra venom factor (CVF) used in other studies (21) , induced significant lung injury alone but this was markedly increased by LPS pretreatment. Neutrophils were not identified in the alveolar spaces after LPS and none was found to be in the process of migration across the endothelium. We have therefore suggested that the increased vascular permeability in the lung in response to zymosan was a result of sequestered neutrophils producing one or more mediators capable of acting directly on the capillary endothelium. Because activated neutrophils are known to release PAF (22, 23) and PAF can increase pulmonary vascular permeability in vivo (15) (16) (17) , we hypothesized that PAF produced locally within the pulmonary capillaries, in response to stimulation with zymosan, may be the mediator involved.
The potent, selective, and long-lasting PAF antagonist, UK-74,505 (24) was therefore used to investigate the involvement of PAF receptors in mediating all or part of the lung injury induced by a combination of LPS plus zymosan. In addition, the effect of PAF receptor blockade after LPS-induced neutrophil sequestration had occurred was investigated by administering UK-74,505 after LPS and before zymosan treatment. The role of PAF in lung injury induced by zymosan alone was also investigated and compared with lung injury induced by CVF.
Materials and Methods

Animals
All studies were conducted on BALB/c female mice (18-20 g; Harlan, Oxford, UK). Animal experiments were performed in accordance with the Animals (Scientific Procedures) Act 1986, UK.
Skin Assay
To confirm the efficacy and duration of action of UK-74,505 as an antagonist of PAF-induced vascular permeability increases in the mouse, a skin model of local edema formation was used. Mice were anesthetized with Hypnorm/Diazepam (16 mg/kg, intraperitoneal), shaved of dorsal skin hair, and the areas for injection were marked out. Iodinated human serum albumin ( 125 I-labeled HSA; Amersham International, Little Chalfont, UK) was injected intravenously (approximately 0.25 Ci/animal) and saline or PAF (1 ϫ 10 Ϫ 9 mol/site) was injected intradermally in duplicate in 50-l volumes. After 30 min, the animals were overdosed with sodium pentobarbitone and killed by exsanguination. Blood samples were collected into heparin and the plasma fractions were prepared. The dorsal skins were removed and skin sites (11-mm diameter) punched out and counted with plasma samples in a ␥ counter (Canberra Packard, Pangbourne, UK). Local edema formation was expressed as microliters of plasma by dividing the counts per minute in skin sites by the counts per minute in 1 l of plasma.
Induction of Experimental Acute Lung Injury
Mice were anesthetized as described above and received an intravenous injection of saline (7 ml/kg) or LPS (3 mg/kg) from Escherichia coli 0111:B4 (Sigma, Poole, UK) and left for 2 h. We have previously demonstrated that this dose of LPS induces an approximately six-fold increase in neutrophil sequestration in the lung after 2 h (as assessed by examination of electron micrographs) but does not result in detectable lung injury (20) . Zymosan A (10 mg/kg) from Saccharomyces cerevisiae (Sigma), or saline in control animals, was then injected intravenously and simultaneously with (25) , was injected intravenously and allowed to circulate for 5 min; 131 I-labeled HSA was used to quantify the intravascular volume of the lung. The mice were then given sodium pentobarbitone to induce deep anesthesia and were killed by exsanguination. A blood sample was collected into heparin and the plasma prepared. The lungs were exposed, removed en bloc , and the activities of 125 I-labeled HSA and 131 I-labeled HSA in whole lungs were counted in a ␥ counter and compared with that in the plasma. Extravascular albumin accumulated in lung tissue, expressed as microliters of plasma, was calculated as Extravascular albumin ϭ (total 125 I-labeled albumin volume) Ϫ (intravascular 131 I-labeled albumin volume)
where the total 125 I-labeled albumin volume is 125 I-labeled albumin counts in lung divided by 125 I-labeled albumin counts in 1 l of plasma, and the intravascular 131 I-labeled albumin volume is 131 I-labeled albumin counts in lung divided by 131 I-labeled albumin counts in 1 l of plasma. In separate groups of animals, zymosan alone (10 mg/kg) or CVF (50 U/kg; Cordis Laboratories, Miami, FL) was injected intravenously together with 125 I-labeled HSA, and increases in pulmonary vascular permeability were assessed after 30 min in the same way as described above. This dose of CVF is similar to that used by Tvedten and coworkers (21) to induce lung injury in mice and was found to be nonlethal in our preliminary studies; 100 U/kg resulted in substantial mortality and the lung injury de-tected in those that survived for 30 min was no different than that seen with the lower dose of CVF.
Extravascular Lung Water
Additional experiments were conducted to determine the extravascular lung water (EVLW) in saline or LPS-and zymosan-treated mice. The calculation of EVLW was based on a method previously described (26) . Briefly, mice were treated with saline or LPS for 2 h, and then zymosan for 30 min. Two minutes before the end of the experiment, a bolus intravenous injection of 125 I-labeled HSA was administered to mark the intravascular space. The mice were then anesthetized and killed by exsanguination as described previously. Exact volume aliquots of whole blood were weighed. The lungs were removed, blotted dry of excess blood, and weighed. The wet lung was then counted in a ␥ counter along with the blood aliquots. The lungs and blood samples were then dried in an oven at 80 Њ C, whereupon they were reweighed. Total lung water was calculated as the difference between the wet weight and dry weight of the lung. EVLW was calculated as the total lung water minus intravascular lung water and expressed as milligrams of water per milligram dry weight.
Treatment with UK-74,505
The PAF receptor antagonist UK-74,505 (a gift from Dr. J. Parry, Pfizer, Sandwich, UK) was dissolved initially in 0.1 M HCl and further diluted 10-fold in saline. In the skin studies, control animals received a bolus intravenous injection of vehicle (0.01 M HCl), whereas the test group received an intravenous injection of UK-74,505 at a dose of 0.5 mg/ kg (27, 28) . Both treatments were given 2 h prior to intradermal injections. This dose was based on considerable experience with the compound in our department (27, 28) and on our preliminary investigations, which revealed this dose to afford maximum inhibition of PAF-induced plasma leakage in skin (data not shown).
In the lung studies, vehicle or UK-74,505 (0.5 mg/kg) was injected intravenously 15 min prior to further intravenous treatment with either zymosan alone or CVF. In combined, sequential LPS and zymosan studies, UK-74,505 was given 15 min before LPS or 15 min before zymosan.
Histology
Following termination, the lungs were exposed and a small catheter was secured into the trachea to permit their inflation with 10% neutral buffered formalin (pH 7.0), until the pleural margins were sharp. The lungs were then removed en bloc and fixed further by immersion in formalin until processing to paraffin wax. Sections (5-to 6-m) were cut and stained with hematoxylin and eosin for assessment of interstitial edema and sequestration of leukocytes in lung parenchyma and noncapillary microvessels (i.e., those with a diameter larger than capillaries and with a well-demarcated wall).
Tissue Extraction and Measurement of Myeloperoxidase Activity
The extent of neutrophil sequestration was quantified by measuring myeloperoxidase (MPO) activity (29, 30) in whole lung tissue. The lungs of animals that had received LPS plus zymosan, zymosan alone, or CVF were removed, weighed, and frozen in liquid nitrogen. On thawing, the tissue was weighed and homogenized in 0.2% NaCl buffer (pH 4.7) and centrifuged at 260 ϫ g for 10 min. The supernatant was isolated and ultracentrifuged at 100,000 ϫ g for 60 min, and the resultant pellet resuspended in 0.5% hexyldecyltrimethyl-ammonium bromide (HTAB). MPO activity in the pellet was assayed by measuring the change in absorbance (optical density [OD]) at 690 nm using tetramethylbenzidine (1.6 mM) and H 2 O 2 (0.3 mM). Results were expressed as change in OD per gram of tissue.
Statistics
All data were expressed as mean Ϯ SEM. One-way analysis of variance (ANOVA) was used for analysis of the data groups. The Student-Newman-Keuls correction factor for multiple comparisons was used as a posttest (InStat 2.01). Differences were considered significant when P values were р 0.05.
Results
Effect of UK-74,505 on PAF-induced Plasma Leakage in Skin
To examine the efficacy and duration of action of UK-74,505 as an inhibitor of PAF-induced vascular permeability increases, a skin model of local edema formation was used. In mice pretreated for 2 h with the vehicle (0.01 M HCl, administered intravenously) plasma leakage in skin sites 30 min after intradermal injection of saline was 1.6 Ϯ 0.2 l ( n ϭ 4) and in sites injected with PAF (1 ϫ 10 Ϫ 9 mol/site) was 6.3 Ϯ 0.6 l ( n ϭ 4; P Ͻ 0.01 compared with saline). When animals were pretreated for 2 h with UK-74,505 (0.5 mg/kg, administered intravenously), PAFinduced edema formation was reduced to 1.4 Ϯ 0.2 l ( n ϭ 4; P Ͻ 0.01), which was not significantly different from saline values in the same animals (1.3 Ϯ 0.2 l). These data show that UK-74,505 is an effective inhibitor of PAFinduced permeability changes in the mouse and that its inhibitory effects last for at least 2 h.
Effect of UK-74,505 on Lung Injury Induced by Combined LPS and Zymosan
In vehicle-treated animals, the accumulation of radiolabeled albumin in extravascular lung tissue in response to subsequent intravenous treatment with saline was 1.1 Ϯ 0.4 l (Figure 1 ). Intravenous administration of LPS followed by zymosan 2 h later resulted in a significant increase in extravascular albumin accumulation in lung tissue measured at 2.5 h ( P Ͻ 0.01); these data are consistent with our earlier findings (20) . Furthermore, EVLW in saline-treated controls was not found to be significantly different from that measured in LPS and zymosan-treated mice. EVLW values were as follows: saline ϭ 3.56 Ϯ 0.4 mg water/mg dry weight ( n ϭ 4); and in the LPS ϩ zymosantreated group, 2.59 Ϯ 0.6 mg water/mg dry weight ( n ϭ 4).
The response to combined LPS and zymosan was similar in animals treated with vehicle ( Figure 1) . However, pretreatment with UK-74,505, 15 min before LPS administration, resulted in 84% inhibition of extravascular albumin accumulation in response to LPS plus zymosan ( P Ͻ 0.01; Figure 1 ). Because UK-74,505 is highly selective for PAF (24, 26, 27) , these data suggest a critical role for PAF in the full development of lung injury in this mouse model.
To define the stage at which PAF was involved in mediating experimental lung injury, a second series of experiments was conducted in which UK-74,505 (or vehicle) was administered after LPS and 15 min before the zymosan. Under these conditions, albumin accumulation in response to LPS plus zymosan was not significantly altered by vehicle treatment (Figure 2) . However, when UK-74,505 was given after LPS but prior to zymosan, the albumin accumulation was reduced by 64% ( P Ͻ 0.05; Figure 2 ). Because the antagonist was less effective when administered in this manner, these data suggest that in addition to inducing neutrophil sequestration, LPS also promotes the production of PAF, which may be involved in priming the sequestered neutrophils.
Effect of UK-74,505 on Lung Injury Induced by Zymosan and CVF
The data presented in Figure 2 indicate that a large proportion of the increase in pulmonary vascular permeability in the lung is the result of PAF production and action in response to zymosan alone. The involvement of PAF as a mediator of vascular permeability induced by zymosan, without LPS pretreatment, was therefore examined. Figure 3 demonstrates that intravenous administration of zymosan (10 mg/kg) induced lung injury over 30 min, as assessed by the extravascular accumulation of albumin, and this was significantly elevated above saline-treated animals. Administration of vehicle did not significantly alter lung injury in response to zymosan alone; however, pretreatment with UK-74,505 significantly decreased zymosan-induced albumin accumulation by 99% ( Figure 3) ; this value was not significantly different when compared with saline-treated controls.
CVF is reported to induce acute lung injury in the mouse (21) . In our hands, intravenous administration of CVF at a dose of 50 U/kg induced lung injury after 30 min that was similar in severity to that seen after zymosan (Figure 4) . This response was not significantly altered by pretreatment with vehicle and, in contrast to the findings with zymosan, UK-74,505 pretreatment did not modify CVFinduced lung injury (Figure 4) .
Effect of UK-74,505 on Neutrophil Sequestration
The histologic profile of lungs taken from saline-treated mice was no different in animals that received vehicle. The lungs were of normal appearance, i.e., alveolar walls were clearly demarcated, without apparent leukocyte sequestra- tion or infiltration of the alveolar spaces, and there was no evidence of interstitial or alveolar edema ( Figure 5A ). In animals treated with zymosan and pretreated with vehicle, there was marked and diffuse sequestration of neutrophils throughout the alveolar-capillary region although there was no migration into the airspaces ( Figure 5B ). There was some evidence of leukocyte aggregates in noncapillary vessels, but no indication of edema formation in the lung tissue. Pretreatment with UK-74,505 did not appear to modify the appearance of the tissue in response to zymosan treatment and neutrophil sequestration remained marked and diffuse throughout the lung ( Figure 5C ).
Pretreatment with UK-74,505 also did not modify the appearance of the lung taken from the LPS-and zymosantreated group (not shown). The associated diffuse accumulation of cells was unaffected and remained distinct with aggregates of neutrophils still visible. Similarly, the sequestration of the neutrophils in the alveolar region in animals given UK-74,505 after LPS and 15 min before zymosan was not altered and, on inspection, distinct aggregates of neutrophils were still present throughout the lung (not shown). In addition, CVF-induced neutrophil sequestration was not modified in mice pretreated with UK-74,505. Neutrophils were still visible in the alveolar walls and in the lumen of large blood vessels (not shown).
The magnitude of neutrophil sequestration was quantified by assay of MPO activity in lung tissue from mice receiving zymosan alone. This technique has been used extensively as a marker of lung neutrophil burden (30) . Zymosan treatment resulted in an approximately 10-fold increase in MPO activity after 30 min ( Figure 6 ) when compared with lung tissue taken from saline-treated controls. Pretreatment with UK-74,505 had no effect on the increased MPO levels, confirming the observations made using light microscopy. LPS plus zymosan treatment resulted in a similar 10-fold elevation of MPO activity when compared with saline-treated controls and this was unaffected by pretreatment with UK-74,505 (data not shown). In addition, UK-74,505 pretreatment had no significant effect on the increase in MPO activity (approximately 10-fold) in lung tissue from animals with CVF (data not shown).
Discussion
Activation of sequestered neutrophils is necessary for the induction of experimental acute lung injury as assessed by measurement of increases in pulmonary vascular permeability, because LPS alone did not induce vascular permeability in mice despite causing an approximately six-fold increase in neutrophil sequestration, as assessed by examination of electron micrographs (21) . The increases in vascular permeability were induced in the absence of neutrophil emigration, consistent with the release and action of agents from neutrophils such as oxygen radicals and proteases, or inflammatory mediators including lipids (PAF, leukotriene B 4 [LTB 4 ]) and chemokines. Activated neutrophils are known to generate and release PAF in response to phagocytic stimuli (22, 23) , and PAF increases microvascular permeability (15) . It is possible, therefore, that endogenously generated PAF may induce endothelial cell retraction, although this has not been investigated in the present study. In this way, pulmonary vascular permeability could be increased in response to treatment with zymosan alone and in the combined LPS and zymosan treatment. Pretreatment of mice with LPS prior to zymosan administration significantly increased the pulmonary vascular permeability although extravascular lung water was not altered when compared with saline-treated controls. Assessment of the lung tissue by light microscopy confirmed this finding, because there was no evidence of edema formation in the LPS-and zymosan-treated animals.
The injury response to zymosan and to combined LPS and zymosan treatment was inhibited by the PAF receptor antagonist UK-74,505. Treatment with UK-74,505 did not have a marked effect on the associated intravascular sequestration and aggregation of neutrophils as assessed by either light microscopy or when quantified by assaying MPO activity in lung tissue. These data suggest that administration of zymosan leads to the synthesis and release of PAF, and that this mediator is involved in the early induction of increased permeability in the lung. The inhibition by UK-74,505 of albumin accumulation in extravascular lung tissue when administered after LPS and prior to zymosan is consistent with this suggestion. Because UK-74,505 is a selective PAF antagonist (24, 27, 28) , the effects of the compound in the current study can be attributed to PAF antagonism. The lung injury measured is known to be neutrophil dependent, because in mice specifically depleted of circulating neutrophils, treatment with zymosan alone or LPS and zymosan in combination failed to induce the accumulation of extravascular albumin in lung tissue (data not shown). Thus, it is possible that the neutrophil is the cellular source of PAF.
The synthesis and release of PAF were specific to activation with zymosan, because in contrast, pretreatment with UK-74,505 had no detectable effect on CVF-induced vascular permeability changes. This was surprising because it is known that both zymosan and CVF can activate the alternative pathway of the complement cascade and suggests that the involvement of PAF was related to the phagocytosis of zymosan particles. The process of phagocytosis is known to stimulate the secretory processes of the neutrophils (31) and during phagocytosis, PAF formation and release are likely to occur (22, 23) . Moreover, zymosan particles can activate their phagocytosis by neutrophils and we have previously found evidence of this process observed in electron micrographs of lung sections, where zymosan particles were identified within neutrophil phagosomes (20) . Other studies have shown that pretreatment with catalase and SOD had a protective effect on CVF-induced lung injury (21, (32) (33) (34) , although the effects of these agents were not tested in the present study. Oxygen radicals (in particular the hydroxyl radical), probably derived from the activated neutrophil, have therefore been proposed as the initiators of vascular permeability changes in the lung in response to CVF.
When UK-74,505 was administered prior to combined LPS and zymosan, there was substantial inhibition of the extravascular accumulation of 125 I-labeled HSA in lung tissue. Similarly, blockade of the PAF receptors also led to a reduction in 125 I-labeled HSA accumulation, when UK-74,505 was given after LPS and before zymosan challenge, although the inhibition of the plasma leakage response was not as great as that seen when administered before LPS (64 versus 84% inhibition). These results (shown in Figures 1 and 2 ) suggest, therefore, that LPS treatment promotes PAF generation. Much of the PAF produced can be retained by the neutrophil, which has led to the suggestion that it has a second-messenger or priming role (35) (36) (37) . If PAF were retained by LPS-stimulated neutrophils in mouse lung, this may explain why LPS alone does not increase microvascular permeability (20) ; the predominant role of the PAF in LPS-stimulated neutrophils in the lung may therefore be priming for enhanced activation/secretion. LPS also stimulates tumor necrosis factor ␣ (TNF-␣) production from macrophages (38) and interleukin-1 (IL-1) production from endothelial cells (39) and these cytokines may also induce priming of neutrophils (40, 41) . Interestingly, because elevated PAF blood levels after endotoxin administration precede increases in TNF-␣ (5) and because a PAF antagonist inhibits endotoxin-induced TNF-␣ increases (42) , it has been suggested that the early generation of PAF plays a crucial role in the subsequent cytokine production, including that of TNF-␣. However, such a pathway may be of limited significance in our model because LPS alone does not result in a vascular leak after 2.5 h (20) .
LPS may also stimulate lung microvascular endothelial cells to generate PAF and a portion of this could remain associated with the cell surface, where it can be coexpressed with P-selectin on activated endothelium (43, 44) . Thus, on contact of the neutrophil with the endothelium, surface-associated PAF can activate the neutrophil via the PAF receptor (45) . Subsequent intracellular signaling events promote the upregulation of CD11/CD18 integrins on the neutrophil cell surface and increased adhesion to ligands including the intercellular adhesion molecule 1 (ICAM-1). We believe that in our model, LPS induces the sequestration of neutrophils within the pulmonary microcirculation at 2 h via ␤ 2 integrins on the neutrophils binding to endothelial ICAM-1. In support of this, monoclonal antibodies to CD11b or ICAM-1 reduce neutrophil sequestration in pulmonary capillaries and the lung injury induced by a combination of LPS and zymosan (20, 46) . The PAF antagonist UK-74,505 is the first agent that we have found to reduce lung injury without an effect on neutrophil sequestration. Neither sequestration nor the aggregation of the neutrophils in lung tissue was altered by pretreatment with the PAF antagonist. This is in line with other reports wherein PAF does not appear to be involved in the adhesion of neutrophils to cytokine-stimulated endothelial cells (47, 48) and is not involved in endotoxin-induced pulmonary leukostasis (5) . The role of P-selectin in the response to LPS in mouse lung is not known despite the observation that it is upregulated in lung tissue 1.5 h after LPS (49) and can be found as early as 5 min (50). It is possible therefore that LPS upregulates P-selectin, which contributes to neutrophil sequestration and injury in our model, but this remains to be investigated.
We suggest that in addition to inducing the sequestration of neutrophils within the pulmonary microcirculation via a combination of expression of ␤ 2 integrin on the neutrophils (20) and perhaps decreased deformability (51), LPS also primes the sequestered cells via PAF and cytokines generated by local cells, including the endothelium. Thereupon, activation by zymosan results in the neutrophils releasing PAF as a mediator that increases vascular permeability to plasma proteins. Although the involvement of PAF in endotoxin-induced pulmonary changes has been previously demonstrated and antagonists of PAF receptors have been shown to attenuate increases in pulmonary vascular permeability (10), the intricate role that PAF production plays in the propagation of lung injury has not been clarified. Furthermore, it will be of value in future studies to evaluate the role of PAF in lung injury associated with bacteremia. The results of our present study suggest that early use of a PAF antagonist and prolonged blockade of PAF receptors, even after the onset of lung injury, would attenuate increases in vascular permeability, thereby limiting extravasation of proteins in lung tissue in patients likely to progress to ARDS.
